Katie Elliott
Family · Guntersville, ALNPI 1649935503
Payments from drug & device makers
Across 129 payments — averaging $21.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$809
- AbbVie$508
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$164
- Exact Sciences$133
- Novo Nordisk$133
- Bayer$121
- plus $953 from 20 others
What the payments were for
- Food & beverage$2,821100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,821 in reported general payments places this provider in the 80th percentile of 3,415 family providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 78 | $113,630 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 110 | $108,397 |
| FarxigaDapagliflozin Propanediol | 102 | $95,758 |
| VraylarCariprazine Hcl | 39 | $58,091 |
| OzempicSemaglutide | 51 | $56,167 |
| TrulicityDulaglutide | 33 | $53,478 |
| RybelsusSemaglutide | 26 | $47,118 |
| JardianceEmpagliflozin | 49 | $40,432 |
| XareltoRivaroxaban | 19 | $27,908 |
| EliquisApixaban | 21 | $25,911 |
| Repatha SureclickEvolocumab | 20 | $21,579 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $19,881 |
| Tresiba Flextouch U-100Insulin Degludec | 13 | $19,834 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 11 | $14,159 |
| LinzessLinaclotide | 16 | $13,822 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $73 | $167,109111 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $809 | $120,844131 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $71 | $116,025125 claims |
| Novo NordiskOzempic, Rybelsus | $133 | $103,28577 claims |
| AbbVieVraylar, Linzess | $508 | $71,91255 claims |
| Johnson & JohnsonXarelto | $13 | $27,90819 claims |
| PfizerEliquis | $120 | $25,91121 claims |
| Astellas Pharma US IncMyrbetriq | $14 | $13,66425 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,415 family providers in Alabama.
Other family in Guntersville
- Taylor PrinceGuntersville$14K
- Justin WilsonCullman$1.1M
- Leigh Ann ChildressHuntsville$240K
- Molly ReevesAuburn$158K
- Christina CanteyHuntsville$118K
- Leigh LunaMontgomery$69K
- Christopher LovellMobile$64K
- Justin SimpsonTuscaloosa$43K
- Kellyn McMahonBirmingham$39K
- Ashley StinesTuscaloosa$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.